A wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd., the company is dedicated to the research and development of innovative biopharmaceuticals, with a strategic focus on cardiovascular and cerebrovascular diseases, metabolic disorders, osteoporosis, oncology, and other therapeutic areas. It has established three innovative drug R&D platforms for recombinant protein drugs, antibody drugs, and antibody-drug conjugates (ADCs), possessing a completely integrated innovative drug development chain covering molecular design, cell line construction, process development, quality research, clinical research, and industrialization. The company has received support from the National Major New Drug Innovation Programs under the national 12th and 13th Five-Year Plans. It has also built a distinctive pipeline in the osteoporosis field, establishing competitive advantage in the domestic osteoporosis market. In addition, it has developed product pipelines in the fields of heart failure, weight loss, lipid-lowering, nephrology, and oncology, with candidates at various stages of development.
More
Affiliated to Shenzhen Salubris Pharmaceuticals Co., Ltd. and located in Maryland, USA. It has gathered many renowned new drug experts focused on early-stage innovative drug development. The company conducts research on novel biopharmaceuticals with globally independent intellectual property rights, enabling synchronous application in China and the U.S., and effectively enhancing the company's international competitiveness in innovative drug research and development.
More
A wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd., primarily engaged in the research, development, production, and sales of biotechnological drugs. The company has established the Suzhou Recombinant Protein Drug Engineering Technology Research Center, with products covering osteoporosis, oncology, diabetes, cardiovascular diseases, and other therapeutic areas, including recombinant proteins and monoclonal antibodies and so on. The manufacturing platform is established in accordance with the requirements of China GMP and EU GMP standards, and includes both prokaryotic and eukaryotic production lines. The eukaryotic production line is the most advanced intelligent 2000L-scale Flexfactory production platform in China, capable of clinical production and commercial production of extracellular expression products such as CHO cells.
More
A wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd., the company is committed to the research, development, and manufacturing of active pharmaceutical ingredients (APIs) in the fields of cardiovascular and cerebrovascular diseases, endocrinology, oncology, nephrology, and other therapeutic areas. Its production lines are established in accordance with both China GMP and EU GMP standards, and has obtained the EU CEP Certificate.
More
A wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd., primarily engaged in the research, development, production, and sales of cephalosporin APIs, chemical APIs, pharmaceutical intermediates, and enzyme products.
More
Affiliated to Shenzhen Salubris Pharmaceuticals Co., Ltd., focusing on the research, development, manufacturing, and sales of high-end interventional medical devices, with a portfolio covering sub-sectors such as cardiovascular, cerebrovascular, and peripheral vascular markets.
More
A wholly-owned subsidiary of Shenzhen Salubris Medtech Co., Ltd., it has innovative medical device products with independent intellectual property rights, and dedicated to the research, development, and commercialization of products in fields such as structural heart disease and peripheral vascular diseases.
More
A wholly-owned subsidiary of Shenzhen Salubris Medtech Co., Ltd., dedicated to the research, development and commercialization of neurointervention and peripheral vascular intervention innovative medical devices. The company has developed the world's first Maurora® Rapamycin Drug-eluting Vertebral Artery Stent, which is the first vertebral artery–dedicated drug-eluting stent approved by the NMPA and commercialized in China.
More
A subsidiary within the consolidated financial statements of Shenzhen Salubris Medical Device Co., Ltd., the company is dedicated to the research, development, and commercialization of products in the field of stroke and related therapeutic areas.
More
A subsidiary within the consolidated financial statements of Shenzhen Salubris Medical Device Co., Ltd., the company is dedicated to the research, development, and commercialization of products in the field of stroke and related therapeutic areas.
More
Affiliated to Shenzhen Salubris Pharmaceuticals Co., Ltd. and located in Hong Kong, China, it has been mainly engaged in trade and technical support services.
More
